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Abstract
Background Early detection of skin cancer is still a major challenge in dermatology practice today. While surveillance
programs are offered to high-risk patients, systematic total-body examination (TBE) in the general population is not
cost-effective. In the past, we demonstrated that a lesion-directed screening (LDS) in the general population delivered
similar detection rates to TBE and was less time-consuming.
Objectives To study whether a lesion-directed early-access consultation can optimize skin cancer detection in derma-
tology practice.
Methods In this observational study, we offered an early-access consultation in patients contacting the dermatology
department concerning 1 or 2 lesions of concern meeting predefined criteria.
Results 342 persons were seen at the dermatology department after triage by phone. Skin cancer detection rate was
13.2% (4.1% for melanoma). If advised/referred by a doctor skin cancer detection rate was 23.6% (9% for melanoma).
With a history of skin cancer, detection rate was 24.3% (4.3% for melanoma). In patients with no referral and a negative
history of skin cancer, detection rate was 7.7% (1.7% for melanoma), which is at least triple the rates reported by popu-
lation-based screening programs. In patients in whom the index lesion was benign, worry of having skin cancer had
decreased significantly by the end of the consultation. Additional total-body examination in these patients had low addi-
tional detection rate (0.5%) and a high number of unnecessary excisions (number needed to excise 13).
Conclusions An early-access dermatology consultation for LDS after triage by phone resulted in high overall skin can-
cer and melanoma detection rates. Our data indicate that performing TBE is especially useful if the index lesion is suspi-
cious. In addition to surveillance programs in high-risk patients, LDS may be a way to optimize skin cancer detection in
the general population and use available time more efficiently in daily dermatology practice.
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Introduction
Despite numerous efforts on primary prevention and early
detection of skin cancer, its global incidence is still rapidly
increasing.1,2 Although melanoma only represents 5 to 10% of
all skin cancers, it is responsible for the majority of skin cancer
deaths and by this brings an important indirect cost to society.1,3
While non-melanoma skin cancers (NMSCs) have low risk of
metastatic spread, early detection can reduce surgical complex-
ity, morbidity and direct costs.4,5
Early detection initiatives need to reduce mortality or at least
morbidity. Several population-based skin cancer screenings have
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been studied. Melanomas were found to be thinner when diag-
nosed through screening.6–8 However, systematic screening in
the general population is not considered cost-effective.2,9,10
Surveillance in high-risk groups is common practice and a sub-
stantial amount of time in dermatology practice may be spent
on this.11–13 Although these groups have a high relative risk, they
do not necessarily make the highest contribution to the absolute
numbers of skin cancer in the total population. Mackie et al.
reported a positive personal history in 2.5% and family history
in 5–11% of patients diagnosed with melanoma.14,15 So, there is
a need for other strategies to detect skin cancer in the general
population.
In the past, we demonstrated that detection rates and cost-ef-
fectiveness of a lesion-directed screening (LDS) were not inferior
to that of a total-body examination (TBE).16 The LDS was over
5 times faster, and additional TBE did not add much value if the
index lesion was benign. This study evaluates whether an LDS
early-access consultation can optimize skin cancer detection in
dermatology practice.
Methods
Patients contacting the dermatology department concerned
about 1 or 2 skin lesions meeting at least one of the criteria
(changed mole, ugly duckling, non-healing lesion, new mole in
an adult (>18 years old) and/or advised/referred by a non-
dermatologist concerning a suspicious lesion) were offered an
early-access consultation preferably within one week. To select
these patients by telephone, the following questions were posed:
‘Does it concern a changing mole’? ‘Does it concern a mole that
looks different than the others’? ‘Does it concern a non-healing
lesion’? ‘Does it concern a new mole’? and ‘were you referred or
advised by a physician to consult concerning this lesion’?.
Patients were always seen by a dermatologist familiar with der-
moscopy. Patients were excluded if they did not meet the above
criteria, were referred by a dermatologist or when the appoint-
ment did not take place within 4 weeks. From February 2017
until March 2017 and October 2017 until July 2019, 342 people
participated in this consultation of which 297 gave their consent.
This study was approved by the Medical Ethics Committee of
the University Hospital Ghent, Belgium. All participants pro-
vided written informed consent.
Outcomes
Three outcomes were evaluated. First, the minimum detection
rate, defined as the number of histologically confirmed malig-
nant lesions divided by the total amount of patients consulting.
Patients who did not give consent to use their data (n = 45)
were considered diagnosed with a benign lesion. Number needed
to excise (NNE) was evaluated. Missing data were not consid-
ered benign but kept out of the calculation of subgroup
detection rates and NNE. Furthermore, anxiety levels were
analysed.
Statistical analysis
Statistical analyses was conducted in SPSS (version 25.0, IBM).
Pearson v2 test was used for comparison of all categorical vari-
ables. The Paired-Samples T-Test and Independent-Samples
T-Test were used for continuous variables. All statistical tests
were two-tailed and P-values <0.05 were considered statistically
significant.








Breitbart et al. (%)
Sex 45
Female 194 65.3 56.2 73.6
Male 103 34.7 43.8 26.4
Education level (n = 254) 88
Primary school 11 4.3 12.5 /
High school 76 29.9 44.7 /
Higher education 86 33.9 32 /
University 81 31.9 10.8 /
Incentive for consultation (N = 254, multiple answers possible) 88
“The lesion looks different than my other moles” 108 42.5 / /
“The lesion of concern has changed” 92† 36.2 / /
“A doctor (non-dermatologist) advised me to see a dermatologist” 87 34.3 / /
“Friends/family advised me to see a dermatologist” 45 17.7 / /
Other reason 13‡ 5.1 / /
†Of these, 82 checked this box of the questionnaire, 10 more were added as they reported a bleeding (4), itching (4) and painful (2) lesion.
‡Reported reasons: personal history of skin cancer (n = 7); information session on skin cancer (n = 1); analysis of the lesion with a mobile app (n = 1); new
lesion (n = 3); non-healing lesion (n = 1).
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Data collection and analyses
Patients were asked to fill in a questionnaire inquiring their rea-
son for consult, demographic information and risk factors. Anx-
iety about skin cancer was questioned through a visual analogue
scale (VAS) from 0 (no anxiety) to 10 (worst anxiety). During
the appointment, a dermatologist examined the lesion(s) of con-
cern and a TBE was completed. The dermatologist noted the
clinical diagnosis of the lesion(s) of concern and documented




In a period of 24 months, 342 individuals qualified for an early-
access lesion-directed dermatology consultation after triage by
phone. Two hundred and ninety-seven patients, presenting
themselves with 313 index lesions were included. When com-
pared with a mean waiting time of 92.5 to 111 days at the
University Hospital dermatology department, the early-access
consultation allowed 43.5% of the patients to consult a derma-
tologist within 1 week, 25.4% within 1–2 weeks and 31.3%
within 2–4 weeks. The mean age was 57 and the male/female
ratio was 1 to 2. Most frequent reasons for consulting were ugly
duckling sign (42.5%), a changed mole (36.2%) and advice by a
physician (37%). Specific reason for consultation, referral and
patient characteristics are summarized in Tables 1 and 2.
Patients were asked a set of yes/no questions concerning
lesion characteristics. Multiple answers were possible. Of all
patients who came on their own initiative (N = 187), 55.1%
(103/187; 75 no answer) reported an ugly duckling lesion (differ-
ent colour/shape/size/structure compared to other lesions),
64.2% (120/187; 42 no answer) reported a changing lesion,
11.2% (21/187; 86 no answer) had observed a non-healing lesion
and 48.7% (91/187; 56 no answer) mentioned a new lesion.
Seventy-nine percent (200/254) of the patients indicated to
have detected the lesion themselves; in 13.5% (34/254) the lesion
was detected by the partner, in 3.2% (8/254) by a friend or fam-
ily member and in 2.8% (7/254) by a physician.
Detection rates
In 79 patients, one of the index lesions was considered suspi-
cious and 45 of these were histologically confirmed to be malig-
nant, resulting in a minimum detection rate of 13.2% (45/342).
Among detected skin cancers, 14 (4.1%) were melanoma, 18
(5.3%) BCC, 12 SCC (3.5%) and 1 T-cell lymphoma (0.3%).





Hoorens et al. (%)
Reference
Breitbart et al. (%)
Skin Type (n = 213) 129
I 39 18.4 6.4 /
II 126 59.0 59 /
III 45 21.2 32.9 /
IV 3 1.4 1.3 /
Number of nevi (n = 238) 104
<25 124 51.9 57.3 /†
25-50 71 30.0 29.3 /†
50-100 28 10.5 10.0 /†
>100 15 6.3 3.4 /†
Presence of actinic keratosis (n = 237) 32 13.5 105 7.9‡ 2.1‡
Presence of solar lentigines on trunk (n = 198) 88 44.2 144 63.7§
Presence of atypical nevi (n = 230) 35 15.2 112 15.4‡ 9.0‡
Family history of skin cancer 11.6 /
Melanoma (n = 252) 15 6.0 92 / 1.1‡
NMSC (n = 245) 18 7.4 99 / /
Personal history of skin cancer (n = 272) 70 25.7 70 2.3 1.6‡
Melanoma (n = 279) 35 12.3 63 / 0.5‡
BCC (n = 268) 30 11.3 74 / /
SCC (n = 268) 9 3.4 74 / /
Merkel cell carcinoma (n = 268) 3 1.1 74 / /
T-cell lymphoma (n = 268) 1 0.4 74 / /
†9.8% on total population had >40 nevi, number of missing data not known.
‡Number of missing data is not known.
§Solar lentigines in total were noted (not only on trunk).
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After TBE 7, additional skin cancers (5 BCCs, 1 SCC and 1 mela-
noma) were detected in patients with a suspicious index lesion,
whereas, only 1 additional skin cancer (BCC) was detected in
patients with a benign index lesion, resulting in detection rates
of 8.9% (7/79) and 0.5% (1/217), respectively.
Thirty seven percent (110 of 297) of the patients were advised
or referred by a doctor (GP or non-dermatologist specialist) to
seek dermatology advice for a specific lesion. In this group, skin
cancer detection rate was 23.6% (26/110) of which 10 melano-
mas (9%), 7 SCC (6.3%) 9 BCC (8.1%)). This was significantly
higher than in patients consulting without a doctor’s advice or
referral (23.6% versus 10.2%; Pearson v2; P = 0.002). Detection
rates were also higher in patients with a personal history of skin
cancer (70/272) compared to patients without a personal history
of skin cancer (24.3% (17/70) versus 11.9% (24/ 201); Pearson
v2, P = 0.01). Detection rate in patients consulting on their own
initiative and without a personal history of skin cancer
(n = 115), was 7.8% (9/115) compared to 21.3% (34/160) in the
patients with a positive history or a physician’s advice/referral
(Pearson v2; P = 0.003). Detection rates in different risk sub-
groups are summarized in Table 3.
Among the lesions initially detected by patients themselves
17.6% (35/199) were malignant (17 BCC, 9 SCC, 9 melanomas);
of those initially detected by the partner 8.8% (3/34) was malig-
nant (3 melanomas) and in case the physician was the first to
detect the lesion 1 in 7 (14.3%) was malignant (1 BCC).
Number needed to excise (NNE)
The number needed to excise (NNE) is defined as the total num-
ber of lesions that has been excised in order to identify one
malignant lesion. Seventy-nine index lesions were considered
clinically suspicious and were planned for excision or biopsy of
which 45 were confirmed to be malignant, resulting in a NNE of
1.8. NNE for melanoma was 2.1 (14 of 29 confirmed), for SCC
1.4 (9 of 13 confirmed) and for BCC 1.2 (17 of 21 confirmed).
In patients with a suspicious index lesion (n = 79), further
TBE resulted in 9 additional excisions of which 7 were con-
firmed malignant (NNE of 1.3). In contrast, additional TBE in
patients with a benign index lesion (n = 217) resulted in 13
additional excisions of which only 1 malignant lesion confirmed
corresponding (NNE of 13).
Anxiety
Seventy-three percent (217/297) of the patients scored their anx-
iety about the index lesion(s) to be skin cancer at the beginning
and the end of the consultation by means of a visual analogue
scale (VAS). Mean VAS score decreased by the end of the con-
sultation both in individuals in whom the index lesion was diag-
nosed benign (4.5 (95%CI: 4.1–4.9) to 0.9 (95%CI: 0.7–1.1)
Paired-Samples T-Test, P < 0.001)) and in individuals in whom
the index lesion was considered suspicious (4.3 (95%CI: 3.6–5.1)
to 3.1 (95%CI: 2.4–3.9); Paired-Samples T-Test; P = 0.003;
Fig. 1). While before start of the consultation VAS scores were
similar, VAS scores after consultation were significantly lower in
the group diagnosed with a benign lesion compared to the group
diagnosed with suspicious lesion (P < 0.001). As a result, the
mean change in VAS scores before and after consultation in
patients with a clinically benign lesion dropped with 3.6 points
compared to only 1.2 points when the lesion was considered sus-
picious (P < 0.001).
Discussion
In this study, we organized an early-access lesion-directed con-
sultation for skin cancer detection after triage by using a tele-
phone questionnaire. Overall, a minimum skin cancer detection
rate of 13.2% was reached, which is 4 up to 6 times higher than
Table 3 Detection rates in patients with referral/advice by non-
dermatologist or a personal history of skin cancer and in patients















Malignant 17 (24.3) 26 (23.6) 9 (7.8)
Melanoma 3 (4.2) 10 (9.1) 2 (1.7)
SCC 4 (5.7) 7 (6.4) 3 (2.6)
BCC 9 (12.9) 9 (8.2) 4 (3.5)
Other
malignant†
1 (1.4) 0 (0) 0 (0)
Benign 53 (75.7) 84 (76.4) 106 (92.2)












Mean VAS anxiety score 
before consultation
Mean VAS anxiety score 
after consultation
Patients with clinically benign lesion (n = 164)b





Figure 1 Anxiety levels before and after consultation in patients
with suspicious or clinically benign lesionsa. aMissing data: 78/297
did not provide VAS scores. bBenign lesions: management was
noted as: no follow-up, follow-up or excision on patients’ initiative.
cSuspicious lesions: management was noted as: excision/biopsy
on dermatologists’ initiative. dPaired-Samples T-Test.
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reported in population-based screenings and probably approxi-
mates detection rates in high-risk patients during surveillance.
The Swiss Euromelanoma campaign reported a detection rate of
1.03% in 2017 ; the German SCREEN project reported an overall
detection rate of 0.8% (0.2% for melanoma).17,18 In our own
population-based study detection rates were 2.4% (0.5% for
melanoma) in the TBE group and 3.2% in the LDS group.16 The
American Academy of Dermatology reported a clinical diagnosis
of skin cancer in 10.8% of the screeners and a confirmed diagno-
sis of melanoma in only 0.1% of the patients.19,20 An important
fraction of detected skin cancers were melanomas for which
early detection has most to gain. The melanoma / NMSC ratio
was 1 in 2 in our series versus 1 in 3 reported in other screening
programs. 16,18 This distinction is most likely related to the crite-
ria used for triage by phone, which were dominated by alerts for
melanoma. The current study resulted a number needed to
excise (NNE) of 1.8 which also favourably compares to other
screening initiatives in population-based settings reporting
NNEs varying from 1.8 up to 20.16,20,21
More than 1 in 5 patients had a personal skin cancer history
and more than 1 in 3 patients were referred by a doctor. Detec-
tion rates in these subgroups were significantly higher {24.3%
[4.2% melanoma] and 23.6% [9.1% melanoma], respectively}.
However in the subgroup without personal history nor referral
by a doctor, skin cancer detection rate was still 7.7% (1.7% for
melanoma), which is at least 3 fold higher compared to other
population-based screenings and has comparable melanoma/
NMSC ratio. In case the index lesion was diagnosed benign the
fear of having skin cancer had dropped significantly by the end
of the consultation, reflecting value for the patient even in the
absence of skin cancer detection.
Subsequent TBE in patients with a clinically benign index
lesion resulted in a low additional detection rate (0.5%) while in
patients with a suspicious index lesion additional detection rate
was 8.9%. These data suggest that TBE after LDS approach is
strongly advisable in case of a suspicious index lesion, but may
be less (cost-)effective in case of a benign index lesion. The latter
is also supported by our previous population-based LDS where
TBE led to an additional detection rate of 0.3% in patients with
a benign index lesion compared to 33% in patients with a malig-
nant index lesion.16 Argenziano et al. reported a risk of missing a
skin cancer if not performing TBE of 2.17%.22 However, this risk
was higher if a skin tumour was the reason for consultation (OR
3.8) and upon presentation of a suspicious lesion in the prob-
lem/uncovered area (OR 6.8). These data suggest that when per-
forming LDS – which we previously demonstrated to only take
about 40 s of time – resulting in the diagnosis of a benign lesion
one could omit additional TBE in the low-risk population. The
latter would take about 3–4 additional minutes and bring a
detection rate of around 0.5% (and a lot of unnecessary biop-
sies/excisions). Our data indicate that we rather spend time on
other individuals worried about a specific lesion (detection rate
of at least 7.7%).23
Efforts to increase sensitization around skin cancer recogni-
tion in the general population and/or the validation of specific
checklists could further optimize preselection.24,25 More specific
in this study there was a higher educational level among partici-
pants compared to our population-based screening (Table 1:
university degree among participants of 31.9% vs 10.8%). Fur-
thermore, it needs to be noted that more than one third of the
study population was advised by a physician, most often the GP,
to consult a dermatologist. This stresses the importance of fur-
ther involving and educating first line healthcare. Offering tools
to the population that can help them preselect may be an attrac-
tive option to reach a more diverse population. Moreover these
techniques may also be of value in case of long travel distances
or infectious disease outbreaks such as the recent COVID-19
pandemic. Unfortunately at this moment existing smartphone
applications using AI systems for diagnosis do not seem ready
for such use in daily practice, although this field is rapidly evolv-
ing.26–28 Teledermoscopy could offer another way to preselect
specific lesions in need of early-access consultation.29–33
Conclusion
An early-access dermatology consultation for LDS after triage by
phone resulted in high overall skin cancer and melanoma detec-
tion rates. Our data support that performing TBE is especially
useful if the index lesion is suspicious.
In addition to surveillance programs in high-risk patients,
LDS may be a way to optimize skin cancer detection and use
available time more efficiently in daily dermatology practice.
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